- Home
- CGTX
as 11-21-2024 4:00pm EST
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 79.3M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 476.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $2.95 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cognition Therapeutics Inc. News
CGTX Breaking Stock News: Dive into CGTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
GlobeNewswire
9 days ago
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
GlobeNewswire
10 days ago
Life Sciences Investor Forum Agenda Announced for November 14th
GlobeNewswire
10 days ago
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
GlobeNewswire
21 days ago
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
GlobeNewswire
23 days ago
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
GlobeNewswire
a month ago
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
GlobeNewswire
a month ago
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
Compare CGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGTX Cognition Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.